Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01933646
Other study ID # V98_23OB
Secondary ID
Status Completed
Phase N/A
First received August 28, 2013
Last updated January 6, 2015
Start date September 2013
Est. completion date September 2014

Study information

Verified date January 2015
Source Novartis
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Observational

Clinical Trial Summary

Evaluate the burden of invasive group B streptococcal (GBS) disease in young infants (up to 90 days of age) in China, in terms of incidence, case fatality rate and serotype distribution


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group N/A to 90 Days
Eligibility Inclusion Criteria:

1. Positive culture for GBS from one or more of the following normally sterile sites: blood, cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, joint fluid, suprapubic bladder aspiration or internal body site (e.g., lymph node, brain).

2. =90 days old at the time of GBS confirmation.

3. Voluntary written informed consent provided.

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Invasive Group B Streptococcal Disease

Locations

Country Name City State
China Site 12 Changsha
China Site 13 Guangzhou
China Site 14 Guangzhou

Sponsors (1)

Lead Sponsor Collaborator
Novartis Vaccines

Country where clinical trial is conducted

China, 

References & Publications (1)

Heath PT, Schuchat A. Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol. 2007 Jun;21(3):411-24. Epub 2007 Mar 2. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of group B streptococcal (GBS) disease From birth to 90 days of age No
Primary Case Fatality Rate of GBS disease From birth to 90 days of age No
Primary GBS serotype distribution From birth to 90 days of age No
See also
  Status Clinical Trial Phase
Recruiting NCT02812576 - Burden of Invasive Group B Streptococcal Disease in Infants and Resistance Surveillance in China N/A
Active, not recruiting NCT01911572 - Genetic Susceptibility to Severe Streptococcal Infections